Table 1.
Published case reports and series of ICI therapy in patients with ESKD on dialysis
| References | Patients (n) | Cancer(s) | ICI(s) | Grades 3/4 irAEs (nonrenal) | Summary of cancer outcomes |
|---|---|---|---|---|---|
| Cavalcante et al. [40] | 2 | Melanoma | Ipilimumab | Pemphigoid rash and bullous lesions | PR (1), CR (1) |
| Alhamad et al. [44] | 1 | Melanoma | Ipilimumab, pembrolizumab | None | PDS |
| Boils et al. [3] | 1 | Lung | Nivolumab | None | N/A |
| Carlo and Feldman [41] | 1 | RCC | Nivolumab | None | PR |
| Chang and Shirai [39] | 1 | Melanoma | Pembrolizumab | None | CR |
| Jose et al. [54] | 1 | Melanoma | Ipilimumab | None | PDS |
| Lipson et al. [2] | 1 | Skin SCC | Pembrolizumab | None | PR |
| Ong et al. [28] | 1 | Melanoma | Nivolumab | None | PR |
| Spain et al. [48] | 1 | Melanoma | Ipilimumab, nivolumab | None | SD |
| Boyle et al. [42] | 1 | Multiple myeloma | Nivolumab | None | PR |
| Park | 4 | RCC (2), skin SCC (2) | Nivolumab (2), pembrolizumab (2) | Grade 3 penumonitis, Grade 4 encephalitis/death (1) | PDS (1), PR (2), death (1) |
| Tabei et al. [24] | 1 | RCC | Nivolumab | None | PR |
| Akturk et al. [45] | 1 | Melanoma | Pembrolizumab, nivolumab | Hypothyroidism | PR |
| Ansari et al. [55] | 1 | RCC | Nivolumab | None | PR |
| Ishizuka et al. [37] | 1 | Lung | Pembrolizumab | None | PR |
| Cheun et al. [6] | 3 | RCC (2), urothelial (1) | Nivolumab (2), atezolizumab (1) | None | PR (1), SD (1), PDS (1), death (1) |
| Fernandez-Diaz et al. [38] | 1 | Melanoma | Nivolumab | None | SD |
| Ito et al. [47] | 1 | RCC | Nivolumab | None | CR |
| Morinaga et al. [30] | 1 | RCC | Nivolumab | None | PDS |
| Osa et al. [27] | 1 | Lung | Pembrolizumab | None | SD |
| Parisi et al. [25] | 1 | Urothelial | Atezolizumab | None | PDS |
| Tachibana et al. [23] | 7 | RCC | Nivolumab | Grade 3 fatigue | PR (1), SD (4), PDS (2), death (2) |
| Vitale et al. [21] | 8 | RCC | Nivolumab | Grade 3 diarrhea, Grade 3 asthenia, Grade 3 anorexia | PR (1), SD (5), PDS (2), death (3) |
| Hirsch et al. [4] | 8 | Cholangiocarcinoma (1), hepatocellular carcinoma (1), Hodgkin’s lymphoma (1), NET (1), RCC (1), urothelial (3) | Atezolizumab (1), nivolumab (2), ipilimumab + nivolumab (1), pembrolizumab (4) | Dermatitis (grade unspecified) | SD (3), PDS (5), death (4) |
| Jain et al. [35] | 8 | Angiosarcoma (1), lung (1), melanoma (2), retroperitoneal sarcoma (2), RCC (1), urothelial (1) | Nivolumab (3), pembrolizumab (5) | Pneumonitis (grade unspecified) | SD (3), PDS (5), death (2) |
| Kuo et al. [33] | 11 | Urothelial | Atezolizumab (3), nivolumab (2), pembrolizumab (6) | Grade 3 anemia (3), Grade 4 anemia (1), Grade 4 neutropenia (1), Grade 4 TEN (1) | PR (6), SD (1), PDS (4), death (3) |
| Osmán-García et al. [26] | 3 | RCC | Nivolumab | None | PR (2), PDS (1) |
| Mejia et al. [31] | 1 | RCC | Ipilimumab + nivolumab | None | PR |
| Murakami et al. [46] | 3 | Skin SCC (2), melanoma | Cemiplimab, pembrolizumab, iplimumab + nivolumab | None | PR (1), SD (2) |
| Strohbehn et al. [1] | 19 | GU (6), melanoma (4), Merkle cell (3), head and neck (3), lung (2), GI (1) | Avelumab (1), atezolizumab (2), ipilimumab (1), ipilimumab/nivolumab (2), nivolumab (5), pembrolizumab (8) | Grades 3–4 myocarditis (1), pneumonitis (1) | SD (4), PDS (9), death (13) |
| Duni et al. [49] | 1 | RCC | Nivolumab | None | SD |
| Tan et al. [22] | 1 | Melanoma | Nivolumab | None | CR |
NET, neuroendocrine tumor; SCC, squamous cell carcinoma; PDS, progressive disease; SD, stable disease; PR, partial response; CR, complete response.